Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979525 | 0.82 | TSHR (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL1156278 | 0.80 | — | — | |
| SCHEMBL27916250 | 0.80 | LMNA (0.36) | TSHRCHRM2CHRM4CHRM1LMNA | |
| SCHEMBL11822812 | 0.80 | TSHR (0.37) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL14981 | 0.79 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL444304 | 0.78 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL219269 | 0.78 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL19395919 | 0.77 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL27712762 | 0.77 | CHRM1 (0.53) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11397951 | 0.77 | ZDHHC7 (0.43) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007011972-A2 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | INVERSEON, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2023046710-A1 | FLOW BATTERIES WITH A NEGOLYTE BASED ON VIOLOGEN AND A HYDROALCOHOLIC SOLVENT | IFP Energies Nouvelles (FR) | 2023-03-30 | — | — | WO | disclosed |
| US-20090214643-A1 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | FRANKLIN AMIE E | 2009-08-27 | — | — | US | disclosed |
| WO-2007011972-A2 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | INVERSEON, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214643-A1 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | ADRB2, ADRB1, ADRA2A | TSHR 545/4885CHRM2 12/4885CHRM4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.